Si-BONE CEO Laura Francis sells $762,012 in company stock

Laura Francis, Chief Executive Officer and a Director at SI-BONE, Inc. (NASDAQ:SIBN), sold 38,006 shares of the company’s common stock on October 12, 2026. The transaction, executed under a pre-arranged 10b5-1 trading plan established on May 21, 2026, totaled $762,012. The shares were sold at prices ranging from $20.00 to $20.1050 per share. The sale came after the stock delivered a 34% return over the past six months, with shares currently trading at $19.47. According to InvestingPro analysis, the stock appears overvalued at current levels based on its Fair Value assessment.

Following the sale, Ms. Francis directly holds 368,129 shares of SI-BONE common stock. This direct ownership includes 355,697 shares issuable upon the settlement of restricted stock units. Additionally, 379,256 shares are indirectly held by The David & Laura Joint Rev Tr.

In other recent news, SI-BONE has reported its second-quarter 2026 results, which exceeded Wall Street’s expectations. The company posted an adjusted loss of $0.09 per share, outperforming analysts’ projections of a $0.16 loss. Additionally, revenue increased by 15.2% to $56 million, slightly surpassing the forecast of $55.92 million. Canaccord Genuity has reiterated a Buy rating for SI-BONE, maintaining a price target of $27.00, following the strong quarterly performance. The company has also raised its revenue and operating expense guidance, citing strong U.S. surgeon engagement and procedural volume growth. Notably, SI-BONE experienced broad-based, double-digit growth across its call points. Despite these positive results, the stock saw a decline in after-hours trading as investors evaluated the company’s outlook and spending plans.